fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-08-27
Biotech partner: Basilea Pharmaceutica (Switzerland) Actelion (Switzerland)
Type of agreement: * commercialization/ distribution
Compound: Toctino® (alitretinoin)
Disease area: severe chronic hand eczema unresponsive to potent topical corticosteroids
Development phase: commercialisation
Nature of the agreement: Basilea Pharmaceutica has entered into an exclusive distribution agreement with Actelion for Toctino® in Canada. The two partners look forward to making Toctino® available to patients in Canada in the fourth quarter of 2010.
Financial terms of the agreement: Under the terms of the agreement, Basilea will be eligible for upfront and milestone payments totaling up to about CAD 3.7 million (€ 0.94 million). Actelion will purchase Toctino® from Basilea and bear all costs related to selling the product in Canada.

Go back to previous page